bioMérieux S.A. (EPA:BIM)
France · Delayed Price · Currency is EUR | Market Cap | 8.60B -42.6% |
| Revenue (ttm) | 3.99B -3.2% |
| Net Income | 462.60M +22.4% |
| EPS | 3.90 +23.0% |
| Shares Out | 117.69M |
| PE Ratio | 18.74 |
| Forward PE | 16.23 |
| Dividend | 0.98 (1.34%) |
| Ex-Dividend Date | Jun 9, 2026 |
| Volume | 26,538 |
| Open | 73.20 |
| Previous Close | 73.10 |
| Day's Range | 73.00 - 73.95 |
| 52-Week Range | 65.60 - 128.30 |
| Beta | 0.57 |
| Analysts | Hold |
| Price Target | 79.04 (+7.17%) |
| Earnings Date | Jul 28, 2026 |
About bioMérieux
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]
Financial Performance
In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BIM stock is "Hold." The 12-month stock price target is €79.04, which is an increase of 7.17% from the latest price.
News
bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual...
bioMérieux Earnings Call Transcript: H1 2026
Q2 2026 delivered a strong rebound with 5% organic sales growth, offsetting a weak Q1 and supporting full-year guidance of 3%-5% sales growth and 0%-10% EBIT growth. Free cash flow surged 76% year-over-year, and the midterm outlook was revised to 3%-6% annual sales growth amid ongoing cost and market pressures.
bioMérieux Earnings release: H1 2026
bioMérieux released its H1 2026 earnings on July 28, 2026, summarizing the period's financial results.
bioMérieux Slides: H1 2026
bioMérieux has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 28, 2026.
bioMérieux Quarterly report: H1 2026
bioMérieux has published its H1 2026 quarterly earnings report on July 28, 2026.
bioMérieux Slides: FY 2026
bioMérieux has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 28, 2026.
bioMérieux Earnings Call Transcript: Q1 2026
Q1 2026 saw a 3.9% sales decline due to weak respiratory demand and geopolitical headwinds, but core reagent growth remained strong. Guidance for 2026 was revised down to 3%-5% sales growth and 0%-10% EBIT improvement, with cost controls and innovation initiatives ongoing.
bioMérieux Earnings release: Q1 2026
bioMérieux released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
bioMérieux Earnings Call Transcript: H2 2025
Sales grew 6.2% organically to €4 billion in 2025, with EBIT up 16% and strong cash flow. 2026 guidance targets 5–7% sales growth and at least 10% EBIT growth, despite headwinds from China and currency. Price erosion remains limited and new launches are expected to drive future growth.
bioMérieux Earnings release: H2 2025
bioMérieux released its H2 2025 earnings on February 27, 2026, summarizing the period's financial results.
bioMérieux Slides: H2 2025
bioMérieux has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 27, 2026.
bioMérieux Annual report: H2 2025
bioMérieux has published its H2 2025 annual report on February 27, 2026.
bioMérieux Earnings Call Transcript: Q3 2025
Q3 2025 saw 3% organic sales growth, strong Spotfire and BioFire non-respiratory performance, but a late respiratory season and China softness led to revised sales guidance of 5.5-6.5% for the year. Profitability remains solid, with cost efficiencies ahead of plan.
bioMérieux Earnings release: Q3 2025
bioMérieux released its Q3 2025 earnings on November 4, 2025, summarizing the period's financial results.
bioMérieux Earnings Call Transcript: H1 2025
H1 2025 saw 9.4% organic sales growth and a significant EBIT margin increase, driven by molecular diagnostics and industrial applications, while China’s decline weighed on microbiology and immunoassays. Free cash flow tripled, and guidance was raised for EBIT growth despite tariff and market risks.
bioMérieux Earnings release: H1 2025
bioMérieux released its H1 2025 earnings on September 4, 2025, summarizing the period's financial results.
bioMérieux Slides: H1 2025
bioMérieux has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 4, 2025.